ArticleScientific reports2026
Gastroprotective and antioxidant effects of stachydrine against indomethacin-induced gastric injury via ERK, AKT and iNOS signaling pathways.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Stachydrine, a major bioactive alkaloid extracted from Leonurus heterophyllus, is a key component of traditional herbal medicine, recognized for its anti-inflammatory and antioxidant properties. In this study, we investigated the gastroprotective effects of stachydrine and its underlying mechanisms in a mouse model of indomethacin (IND)-induced gastric injury. Mice were intragastrically administered IND at a dose of 40 mg/kg, followed 30 min later by treatment with varying doses of stachydrine (0, 5, and 10 mg/kg). Six hours post-IND administration, animals were sacrificed for further analysis. The results demonstrated that stachydrine treatment effectively attenuated IND-induced acute gastric injury, as evidenced by reduced gastric myeloperoxidase activity, and pro-inflammatory cytokine production (TNF-α, IL-6, and IL-1β). Stachydrine also significantly decreased gastric malondialdehyde activity while enhancing superoxide dismutase activity. Furthermore, it suppressed the expression of extracellular signal-regulated kinase (ERK), protein kinase B (AKT), and inducible nitric oxide synthase (iNOS) expressions. These findings indicate that stachydrine confers gastroprotection against IND-induced gastric injury, potentially by suppressing inflammatory and oxidative stress responses, inhibiting the ERK, AKT and iNOS signaling pathways. Thus, stachydrine may serve as a promising candidate for the treatment of IND-induced gastric injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.